Immunotherapy‐Induced Type 1 Diabetes Mellitus Causing Diabetic Ketoacidosis: A Case Report and Review of Current Guidelines

Patrick Disterhaft, Caleb Kerr, Daniel Barnett, Moti Salloum · 2024

Read Immunotherapy‐Induced Type 1 Diabetes Mellitus Causing Diabetic Ketoacidosis: A Case Report and Review of Current Guidelines by Patrick Disterhaft, Caleb Kerr, Daniel Barnett, Moti Salloum (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11574678.txt.

Description

A peer-reviewed research article from Europe PMC (2024). BackgroundImmune checkpoint inhibitors (ICIs) are becoming more frequently used in the treatment of many types of malignant cancers by disinhibiting T‐cell activation, which promotes the destruction of cancer cells. This disinhibition can also result in autoimmune conditions, like endocrinopathies.CaseWe report a case of a 78‐year‐old male patient with malignant mesothelioma treated with combination ICI therapy who presented with diabetic ketoacidosis (DKA) with no history of diabetes mellitus or hyperglycemia.

Catalog record

CREATORPatrick Disterhaft, Caleb Kerr, Daniel Barnett, Moti Salloum
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE19 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11574678

Browse the full library · About the Tower of Babel